With varied expertise in Clinical Trials phase II, III and IV, Susan Feyerabend is the ideal contact person to Sponsors, Clinical Research Organisations and the Independant Review Board (IRB) helping to optimize the design of a study. Frequently she is appointed National Coordinating Investigator in Germany.
Susan Feyerabend, MD is appointed National Coordinating Investigator (LKP) in Germany:
- Astellas Serenity 6294-CL-0101
- Ferring Degarelix-FE200486 CS-35A
- Astellas Preside 9785-MA-1001
- Aquinox Pharma AQX-1125-30
- AstraZeneca Profound D081DC00007
- Astellas 9785-CL-0123
- Clovis Oncology Atlas CO-338-085